Nutritional Regimes Enriched with Antioxidants as an Efficient Adjuvant for IBD Patients under Infliximab Administration, a Pilot Study

Marina Liso 1,†, Annamaria Sila 1,‡, Giulio Verna 2,3,©, Aurelia Scarano 4,©, Rossella Donghia 1, Fabio Castellana 4,©, Elisabetta Cavalcanti 1,©, Pasqua Letizia Pesole 1,©, Eduardo Maria Sommella 2, Antonio Lippolis 1,©, Raffaele Armentano 1,©, Anna Maria Giudetti 5,©, Daniele Vergara 5,©, Pietro Campiglia 2,©, Rodolfo Sardone 1,©, Margherita Curlo 1, Mauro Mastronardi 1, Katia Petroni 6,©, Chiara Tonelli 6,©, Angelo Santino 4,*,† and Marcello Chieppa 1,7,*,†

Abstract: Antioxidants are privileged candidates for the development of adjuvants able to improve the efficiency of pharmacological therapies, particularly for chronic inflammatory syndromes. During the last 20 years, anti-TNFα (tumor necrosis factor alpha) monoclonal antibodies infusion has been the biological therapy most frequently administered but there is still large space for improvement in disease remission rates and maintenance. In this context, nutritional bioactive compounds contained in dietary patterns or included as supplements, may act as adjuvants for the induction and maintenance of IBD (inflammatory bowel diseases) remission. To verify this possibility, a single-center preliminary study (SI-CURA, Soluzioni Innovative per la gestione del paziente e il follow up terapeutico della Colite Ulcerosa) was designed and carried out to evaluate whether a daily administration of purple corn supplement could improve the response to Infliximab (IFX) infusion of IBD patients with both Crohn’s disease (CD) and ulcerative colitis (UC). A cohort of 47 patients was enrolled in the study. Biological samples were collected before the first and the third IFX infusion. All patients received nutritional guidelines, 27 of them received commercial red fruit tea with low anthocyanins content, while 20 received a purple corn supplement with a high anthocyanin content. Results show that the administration of an antioxidant-enriched purple corn supplement could improve IFX-mediated disease remission in terms of circulating inflammatory markers. Comparison between CD and UC patients revealed that, at this anthocyanin dosage, the purple corn extract administration improved disease remission rates and maintenance. In this context, nutritional bioactive compounds contained in dietary patterns or included as supplements, may act as adjuvants for the induction and maintenance of IBD (inflammatory bowel diseases) remission. To verify this possibility, a single-center preliminary study (SI-CURA, Soluzioni Innovative per la gestione del paziente e il follow up terapeutico della Colite Ulcerosa) was designed and carried out to evaluate whether a daily administration of purple corn supplement could improve the response to Infliximab (IFX) infusion of IBD patients with both Crohn’s disease (CD) and ulcerative colitis (UC). A cohort of 47 patients was enrolled in the study. Biological samples were collected before the first and the third IFX infusion. All patients received nutritional guidelines, 27 of them received commercial red fruit tea with low anthocyanins content, while 20 received a purple corn supplement with a high anthocyanin content. Results show that the administration of an antioxidant-enriched purple corn supplement could improve IFX-mediated disease remission in terms of circulating inflammatory markers. Comparison between CD and UC patients revealed that, at this anthocyanin dosage, the purple corn extract administration improved the IFX response in CD but not in UC patients. Our results may pave the way for a new metacentric study of CD patients, recruiting a wider cohort and followed-up over a longer observational time.
Keywords: antioxidant; anthocyanins; IBD; diet; infliximab; pilot study

1. Introduction

Inflammatory bowel diseases (IBD), including Crohn’s Disease (CD) and Ulcerative Colitis (UC), are multifactorial disorders characterized by chronic inflammation of the gut, abdominal pain, diarrhea, and rectal bleeding. Inflammation in CD involves the entire gastrointestinal tract, whereas in UC only the colon and the rectum are affected. Transmural inflammation is typical of CD, while in UC the inflammation is confined to the mucosa [1–3].

During the past few decades, IBD treatment has made remarkable advances, mainly related to the availability of monoclonal antibodies to block several elements of the immune and inflammatory response. IBD patients were originally treated with corticosteroids and thiopurines, and basically no other therapeutic options were available until the introduction of the first hybrid anti-tumor necrosis factor alpha (TNFα)-antibody in 1995 [4].

Currently, the administration of infliximab (IFX), a chimeric monoclonal antibody against TNFα, is a common strategy even used as the first or initial therapy, as it can induce mucosal healing and reduce the need for surgical intervention more frequently than corticosteroids or thiopurines [5,6]. Despite these results, IFX administration is frequently unable to induce long-term IBD remission, as a significant percentage of patients fail to respond and others experience a secondary loss of response [7]. As most patients are young at IBD onset, treatment goals are typically focused first on inducing disease remission and then on maintaining clinical remission and preventing the onset of complications.

Epidemiological data clearly indicate that the IBD prevalence is increasing in Eastern societies, in parallel with the change in lifestyle habits and diet. Nutritional components of the diet can favor the growth of specific bacterial strains, triggering disease progression [8–11].

Western diets often have a poor content of anthocyanins and polyphenols, natural anti-inflammatory molecules that can potentially be used as adjuvants to the anti-TNFα therapy in the form of extracts from functional foods. Epidemiological studies demonstrated that the consumption of anthocyanins-rich foods can protect from numerous diseases including cancer, cardiovascular disease, and age-related neurodegenerative diseases, all characterized by deregulated inflammation status [12–17].

In particular, it is well known that polyphenols suppress inflammatory cytokine secretion by immune cells exposed to bacterial components [18–20]. Polyphenols, such as quercetin, are potent iron sequestering agents that can reduce iron concentration by inducing the expression of Slpi (Secretory leukocyte protease inhibitor) and HO-1 (Heme oxygenase-1) [21–24]. These proteins, in turn, can block the inflammatory cascade and free radicals formation [25]. Furthermore, the administration of a polyphenol-enriched diet was able to modify the intestinal microbiota diversity in a murine model of IBD [26–28], thus suggesting that specific nutritional regimes may block the trigger for disease recurrence in IBD patients.

Oxidative stress is a well-accepted component of the IBD pathology, often considered a result of the ongoing chronic inflammation, even though recent data demonstrated a lower antioxidant capacity of patients in remission versus the control group [29]. Furthermore, recent data suggest that diet and an abundance of microbial species may boost the generation of pro-oxidant molecules in the gastrointestinal tract [30].

In light of these results, we designed a pilot interventional study to address the possibility of using antioxidant-enriched complementary approaches to improve IBD patients’ clinical response to IFX infusion, and reduce the risks of secondary loss of response. In the study group, we administered a daily single dose of anthocyanin-rich supplement obtained from purple corn. This supplement is a high-anthocyanin water-soluble extract, obtained from B1 PI1 purple corn cobs. In previous studies, the purple corn supplement was reported to protect from myocardial damage induced by Doxorubicin, an anthracycline widely used...
as a chemotherapeutic drug against a variety of cancer types [31]. Administration of purple corn extract reduced the development of trigeminal inflammatory pain in rats and decreased obesity-associated inflammation, by preventing recruitment and proliferation of adipose tissue macrophages and promoting their shift towards an anti-inflammatory phenotype [32,33].

2. Materials and Methods

2.1. Study Design

This single-center study was based on the administration of a purple corn supplement to IBD patients (Crohn’s disease and ulcerative colitis) receiving infliximab between September 2019 and December 2020 at the Division of Gastroenterology and Digestive Endoscopy of the National Institute of Gastroenterology “S. de Bellis”, Castellana Grotte, Bari, Italy.

The experimental design of our study consisted of nutritional intervention in a heterogeneous group of 47 IBD patients (22 with CD and 25 with UC) at the start of the IFX infusion (Figure 1). The day of the first infusion is denominated time zero (T0) hereafter in the study. Patients were randomly subdivided into 2 groups: the diet + red fruit tea (RFT) or diet + purple corn extract (RED). The first group of patients received a normocaloric nutritional regime and a daily dose of commercial red fruit tea (total polyphenols content about 2 mg GAE/g DW (gallic acid equivalents per g of dry weight); total anthocyanin content of 0.5 mg cyanidin 3-glucoside (C3G) equivalents/g DW), the second group received the same normocaloric diet plus a daily dose of purple corn extract (with a flavor similar to red fruit tea) [31,33]. The RFT group included 27 patients (15 males and 12 females), 13 affected by CD and 14 by UC. The RED group included 20 patients (8 males and 12 females), 9 with CD and 11 with UC. Patients’ disease was monitored before each IFX infusion, and blood samples were collected before the first and the third anti-TNF infusion (T0 and T3, respectively), as shown in Figure 1.

A comprehensive assessment of patients’ circulating biomarkers and abundance of inflammatory mediators was performed before the T0 and T3, together with routine disease assessments.

The treatment goal, after 8 weeks of therapy (T3), was a decrease by at least 6 points in the Mayo and Montreal scores [34,35], independently of the starting score. Inclusion criteria were: patients scheduled treatment with anti-TNFα therapy, therapy to be performed with either Remicade® (Janssen, Beerse, Belgium) or the biosimilar Remsima® (Celltrion, Incheon, Korea), (5 mg/kg body weight), and no previous treatment with anti-TNFα therapy. Exclusion criteria were comorbidities with other diseases (assessed with the Charlson Comorbidity Index) [36], pregnancy or breastfeeding, a malignant neoplasm in the last 10 years, ongoing immunosuppressive or immunomodulatory therapy, and the need for artificial nutrition.

2.2. Ethics Statement

The investigation was conducted following the ethical standards, the Declaration of Helsinki, and international guidelines, and had been approved by the authors’ institutional
review board (Number 333, 31 July 2019). All patients provided written informed consent to take part.

2.3. Assessment of Participants

Study subjects’ initial evaluation included a medical history, physical examination, and lab tests, including complete blood count (CBC) with differential C-reactive protein (CRP), albumin, iron, ceruloplasmin, alpha-1 antitrypsin, transferrin, vitamin D, ferritin, folates, and vitamin B12.

Patients underwent clinical follow-up at 2 and 8 weeks. Standardized questionnaires about the general symptoms and adverse effects were completed during each study visit [25]. In addition, patients underwent a physical examination, and the same blood work was performed at the enrollment and follow-up visits.

2.4. Dietary Therapy Management

A total of two dietary regimes were adopted. The first group followed a normocaloric diet consisting of a maximum daily intake of 2075.70 Kcal, supplemented with a daily intake of one cup of a commercial red fruit tea (RFT); the other group followed the same normocaloric diet supplemented with a daily cup of purple corn extract (RED). The diet consisted of about 18.81% of proteins, 22.34% of fats, 58.54% carbohydrates [37,38], and was created using the software WinFood 3.29 software (Medimatica Srl Unipersonale, Colonnella, Italy). The detailed bromatological composition is indicated in Table S1.

At the enrollment following the nutritional care process, the nutritional assessment was performed with the recall-24h diary. Then, patients’ anthropometric parameters (weight, height, Body Mass Index, and waist, calf, and triceps circumference) and blood pressure were recorded. During the first visit, patients filled out the MNA (Mini Nutritional Assessment) and MUST (Malnutrition Universal Screening Tool) questionnaires [39,40]. Patients were randomly assigned to the RFT or the RED group and started the nutritional regime. When enrolled in the study, all patients were instructed how to correctly prepare the supplement breakfast infusion, thus the nutritionist was not blinded, whereas the physicians and final analysts were blinded. The RFT or RED supplements were taken every day at breakfast. Patients were strongly advised to follow the nutritionist’s suggestions, to introduce new foods gradually and in a sequential manner, according to their symptoms and necessities. The nutritional regime consists of a balanced Mediterranean Diet with a total fibers content based on the Recommended Dietary Allowance (RDA) and a great variety of foods; seasonal fruit and vegetables were strongly recommended. The goal of the nutritional intervention was to educate patients about a healthy and balanced diet, to treat any eventual ongoing malnutrition, and to prevent IBD disease recurrence and consequent hospitalization.

2.5. Supplement Composition

The supplement is extracted from B1 Pl1 purple corn cobs using ethanol:H2O (30:70 v/v) at 55 °C for 1 h, titrated to a concentration of 4% anthocyanins and spray-dried to obtain water-soluble granules packaged in single-dose packs (Sveba Srl, Appiano Gentile, CO, Italy) [31,33]. The RED was drunk once a day, offering a 125 mg total daily dose of anthocyanins per day, already proven to be safe and well-tolerated [41].

2.6. Sample Collection and Cytokine Detection

Before and during the follow-up visit, 10 mL of blood were collected and stored at −80 °C in the institute biobank. Circulating cytokine detection was performed using the ELISA kit (R&D Systems, Minneapolis, MN, USA) for IL-1β and “MACSplex Cytokine 12 Kit human” (Miltenyi Biotec, Bergisch Gladbach, Germany) for GM-CSF, IFN-α, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-17A, and TNFα, following the manufacturer’s instructions. Flow Cytometry acquisition was performed using NAVIOS (Beckman Coul-
ter, Brea, CA, USA). Flow cytometry analysis was performed using Kaluza Software 1.5 (Beckman Coulter, Brea, CA, USA).

2.7. Statistical Analysis

The entire sample consisted of 47 subjects assessed at baseline (T0) and at follow-up time (T3, after 8 weeks of therapy). All data are shown as mean ± SD, median (min to max) for categorical variables, and as N (%) for categorical ones. The normality of distributions was assessed with the Shapiro–Wilks test. A non-parametric paired approach was chosen to test differences between the T0 and T3 observations (Wilcoxon sum rank test for paired samples). A *p*-value ≤ 0.05 was considered statistically significant. Mann–Whitney sum rank test and Fisher’s exact test were performed to assess statistically significant differences between the RFT and RED groups for continuous and categorical variables, respectively.

3. Results

3.1. Baseline Characteristics

Clinical and pathological features of the enrolled patients are depicted in Table 1. There was a high grade of heterogeneity in terms of age and gender in our sample cohort. We enrolled 22 CD patients and 25 UC patients; 42.55% were smokers.

Table 1. Clinicopathologic features of enrolled patients (N: 47).

|                            | T0                  | Median (Min to Max) |
|---------------------------|---------------------|---------------------|
| Proportions N (%)         | 47 (100.00)         | 42.5 (17 to 70)     |
| Age (years)               | 42.12 ± 14.44       | 42.5 (17 to 70)     |
| Gender N (%)              |                     |                     |
| Male                      | 24 (51.10)          |                     |
| Female                    | 23 (48.90)          |                     |
| Disease N (%)             |                     |                     |
| CD                        | 22 (46.80)          |                     |
| UC                        | 25 (53.20)          |                     |
| Smokers N (%)             | 20 (42.55)          |                     |
| Time from diagnosis to starting IFX (months) | 78.19 (58.18)       | 64 (10 to 240)      |
| Type of Disease N %)-Montreal Classification |                     |                     |
| B1-Inflammatory           | 12 (54.55)          |                     |
| B2-Stricturing            | 6 (27.27)           |                     |
| B3-Penetrating            | 4 (18.18)           |                     |
| Location of CD disease patients N %)-Montreal Classification |                     |                     |
| L1 Ileal                  | 3 (13.64)           |                     |
| L2 Colic                  | 1 (4.55)            |                     |
| L3 Ileocolic              | 18 (81.81)          |                     |
| Location of UC disease patients N %)-Montreal Classification |                     |                     |
| E1 Ulcerative             | 0 (0.00)            |                     |
| E2 Left sided UC (distal UC) | 0 (0.00)           |                     |
| E3 Extensive UC (pancolitis) | 25 (100.00)       |                     |
| Steroid therapy (%)       | 22 (46.81)          |                     |

The disease phenotype according to the Montreal Classification was inflammatory in 54.55% of our CD patients, stricturing in 27.27%, and penetrating in 18.18%. A total of 13.64% of CD patients had ileal disease while 4.55% had a colic phenotype and the majority of them (81.81%) had an ileocolic phenotype. All the UC patients (100%) had a pancolitis disease phenotype.

Before the enrollment, 46.81% of the patients had been taking ongoing steroid therapy.
3.2. Inflammatory Biomarkers Modulation after 8 Weeks of Therapy

Patients were enrolled in the study on the day of the first IFX infusion (T0). All 47 patients completed the study and no dropout occurred.

Figure S1 and Table 2 show patients’ characteristics and serological data at T0 and after 8 weeks of therapy (T3).

Table 2. Description of the whole sample across follow-up times (N:47). Statistically significant differences (p-value ≤ 0.05) are underlined in bold.

|                  | T0       | Median (Min to Max) | T3       | Median (Min to Max) | p-Value |
|------------------|----------|---------------------|----------|---------------------|---------|
|                  | Mean ± SD|                      | Mean ± SD|                      |         |
| CDAI (Crohn’s Disease Activity Index score, CD patients) | 288.09 (60.73) | 286.5 (168 to 414) | 209.68 (57.64) | 204 (137 to 371) | <0.0001 |
| Mayo score (UC patients) | 13.64 (2.78) | 14 (7 to 19) | 8.64 (2.75) | 9 (4 to 14) | <0.0001 |
| GM-CSF (pg/mL)   | 1.29 ± 5.13 | 0 (0 to 32.37) | 1 ± 4.84 | 0 (0 to 32.05) | 0.14    |
| IFN-α (pg/mL)   | 7.87 ± 4.65 | 9.05 (0 to 17.43) | 7.38 ± 4.66 | 9.45 (0 to 14.65) | 0.90    |
| IFN-γ (pg/mL)   | 44.23 ± 120.39 | 0 (0 to 662.92) | 41.85 ± 110.29 | 0 (0 to 662.92) | 0.60    |
| TNFα (pg/mL)    | 8.83 ± 36.19 | 0 (0 to 232.08) | 6.54 ± 32.23 | 0 (0 to 217.51) | 0.07    |
| CRP (mg/dL)     | 1.59 ± 2.06 | 0.64 (0.05 to 7.85) | 0.74 ± 1.19 | 0.15 (0.05 to 5.29) | <0.01   |
| IL-10 (pg/mL)   | 39.31 ± 73.16 | 30.56 (0 to 441.55) | 41.24 ± 68.24 | 31.06 (0 to 431.89) | 0.69    |
| IL-12 (pg/mL)   | 53.54 ± 196.61 | 0 (0 to 1145.63) | 44.03 ± 176.04 | 0 (0 to 1134.84) | 0.42    |
| IL-17A (pg/mL)  | 3.44 ± 5.92 | 2.3 (0 to 36.23) | 3.35 ± 5.56 | 0 (0 to 34.69) | 0.82    |
| IL-2 (pg/mL)    | 0.48 ± 3.35 | 0 (0 to 23.19) | 0.52 ± 3.57 | 0 (0 to 24.72) | 0.95    |
| IL-4 (pg/mL)    | 20.81 ± 37.44 | 5.18 (0 to 215.53) | 18.52 ± 36.48 | 3.39 (0 to 228.54) | 0.51    |
| IL-5 (pg/mL)    | 9.84 ± 34.55 | 0 (0 to 199.9) | 6.59 ± 23.85 | 0 (0 to 147.07) | 0.10    |
| IL-6 (pg/mL)    | 3.63 ± 18.02 | 0 (0 to 106.12) | 1.01 ± 6.98 | 0 (0 to 48.38) | 0.37    |
| IL-9 (pg/mL)    | 15.72 ± 50.43 | 0 (0 to 299.73) | 15.09 ± 47.5 | 0 (0 to 290.69) | 0.75    |
| IL-1β (pg/mL)   | 9.88 ± 21.29 | 1.78 (0 to 126.75) | 23.28 ± 110.19 | 2.37 (0 to 765.91) | 0.67    |
| Folate (ng/mL)  | 6.87 ± 5.59 | 4.95 (1.9 to 28) | 8.14 ± 6.63 | 6.4 (1.7 to 28) | 0.05    |
| Vitamin B12 (pg/mL) | 267.75 ± 141.19 | 244.5 (69 to 682) | 245.98 ± 114.12 | 220 (83 to 566) | 0.03    |
| Vitamin D (ng/mL) | 21.59 ± 10.29 | 19.45 (4.8 to 65.5) | 20.21 ± 8.03 | 20.2 (4.6 to 46.4) | 0.12    |

None of the 47 patients recruited was a primary non-responder, so the entire group was able to complete the experimental protocol until the T3 (third infusion).

Unsurprisingly, IFX administration resulted in a reduction of inflammatory scores (both significant, CDAI, and Mayo) and serological markers, independently of which antioxidant-rich supplement was administered. Importantly, T3 patients also displayed increased concentration of iron and folate (Table S2), most likely due to the reduced intestinal permeability, blood loss, and watery stools as a consequence of the IFX-mediated mucosal healing [42]. Circulating TNFα concentration was reduced in patients treated with IFX, when considering the mean of TNFα levels, although the concentration in several patients was under the detection limit even before the onset of IFX administration.

Serum analysis at T3 revealed differences between the RFT and RED groups of patients. Figure S2, Table 3 and Table S3 show an analysis of the diet with commercial red fruit tea (RFT) vs. the diet with purple corn extract (RED) group at T3. Despite IFX being administered to both groups, CRP, ceruloplasmin, and TNFα were significantly more reduced in the group receiving the RED. The increased folate circulating levels, following IFX administration, were not significantly different between the groups at T3 (p = 0.06), although an evident increase was observed in the RED group. Conversely, the iron concentration decreased, but not significantly, in the RED group as compared to the RFT group at T3.
Table 3. Description of the whole sample in T3 according to the type of treatment. (N: 47). Statistically significant differences (p-value ≤ 0.05) are underlined in bold.

| T3 | RFT | RED |
|----|-----|-----|
| Mean ± SD | Median (Min to Max) | Mean ± SD | Median (Min to Max) | p-Value |
| Proportions (%) | 27 (57.40) | 20 (42.60) | | | |
| Age (years) | 40.26 ± 12.33 | 36 (19 to 69) | 45.4 ± 16.71 | 47.5 (17 to 70) | 0.29 |
| Gender | | | | | |
| Male | 15 (55.60) | 8 (40.00) | | | |
| Female | 12 (44.40) | 12 (60.00) | | | |
| Disease | | | | | |
| CD | 13 (48.10) | 9 (45.00) | | | |
| UC | 14 (51.90) | 11 (55.00) | | | |
| GM-CSF (pg/mL) | 1.78 ± 0.64 | 0 (0 to 32.05) | 0 ± 0 | 0 (0 to 0) | 0.07 |
| IFN-α (pg/mL) | 7.02 ± 4.69 | 9.45 (0 to 11.45) | 7.59 ± 4.67 | 9.25 (0 to 14.65) | 0.99 |
| IFN-γ (pg/mL) | 61.09 ± 140.83 | 0 (0 to 662.92) | 15.71 ± 41.3 | 0 (0 to 153.83) | 0.09 |
| TNFα (Detectable) | 6 (22.20) | | | | |
| CRP (mg/dL) | 0.87 ± 1.07 | 0.31 (0.05 to 3.8) | 0.56 ± 1.33 | 0.05 (0.05 to 5.29) | 0.03 |
| IL-10 (pg/mL) | 55.45 ± 85.88 | 32.06 (0 to 431.89) | 22.02 ± 27.41 | 0 (0 to 75.96) | 0.12 |
| IL-12 (pg/mL) | 73.19 ± 231.55 | 0 (0 to 1134.84) | 6.87 ± 23.05 | 0 (0 to 98.36) | 0.32 |
| IL-17A (pg/mL) | 4.36 ± 6.91 | 2.76 (0 to 34.69) | 1.88 ± 2.68 | 0 (0 to 10.4) | 0.11 |
| IL-2 (pg/mL) | 0.92 ± 4.76 | 0 (0 to 24.72) | 0 ± 0 | 0 (0 to 0) | 0.41 |
| IL-4 (pg/mL) | 25.34 ± 45.52 | 10.55 (0 to 228.54) | 7.4 ± 13.59 | 0 (0 to 49.54) | 0.06 |
| IL-5 (pg/mL) | 11.1 ± 31.14 | 0 (0 to 147.07) | 0.82 ± 3.68 | 0 (0 to 16.44) | 0.09 |
| IL-6 (pg/mL) | 1.79 ± 9.31 | 0 (0 to 48.38) | 0 ± 0 | 0 (0 to 0) | 0.41 |
| IL-9 (pg/mL) | 23.13 ± 61.23 | 0 (0 to 290.69) | 4.98 ± 15.46 | 0 (0 to 56.2) | 0.19 |
| IL-1β (pg/mL) | 34.13 ± 146.54 | 1.93 (0 to 765.91) | 6.34 ± 8.5 | 3.36 (0 to 25.93) | 0.88 |
| Folate (ng/mL) | 7.07 ± 6.53 | 4.5 (1.7 to 28) | 9.58 ± 6.65 | 7.05 (2.6 to 25) | 0.06 |
| Vitamin B12 (pg/mL) | 260.44 ± 121.62 | 235 (83 to 533) | 226.45 ± 102.92 | 207 (96 to 566) | 0.32 |
| Vitamin D (ng/mL) | 20.07 ± 8.62 | 21.8 (4.6 to 39.3) | 20.4 ± 7.38 | 19.45 (13.2 to 46.4) | 0.69 |

Diet may act differently on CD or UC. Figure 2, Table 4 and Table 5 show the impact of RFT and RED on CD, according to the type of treatment. (N: 22). Statistically significant differences (p-value ≤ 0.05) are underlined in bold.

Table 4. Description of the whole sample at follow-up observation (T3) in CD patients, according to the type of treatment. (N: 22). Statistically significant differences (p-value ≤ 0.05) are underlined in bold.

| CD | RFT | RED |
|----|-----|-----|
| Mean ± SD | Median (Min to Max) | Mean ± SD | Median (Min to Max) | p-Value |
| Proportions (%) | 13 (59.10) | 9 (40.90) | | | |
| Age (years) | 37.8 ± 11.6 | 37 (19 to 59) | 45.67 ± 18.25 | 47 (17 to 70) | 0.20 |
| Gender | | | | | |
| Male | 7 (53.80) | 5 (55.60) | | | |
| Female | 6 (46.20) | 4 (44.40) | | | |
| GM-CSF (pg/mL) | 2.89 ± 8.8 | 0 (0 to 32.05) | 0 ± 0 | 0 (0 to 0) | 0.04 |
| IFN-α (pg/mL) | 8.39 ± 3.79 | 9.85 (0 to 11.45) | 7.66 ± 4.4 | 9.45 (0 to 11.45) | 0.58 |
| IFN-γ (pg/mL) | 96.3 ± 185.69 | 0 (0 to 662.92) | 0 ± 0 | 0 (0 to 0) | 0.02 |
| TNFα (pg/mL) | 61.17 (35.50) | 5 (38.50) | | | |
| CRP (mg/dL) | 0.98 ± 1.35 | 0.4 (0.05 to 3.8) | 0.13 ± 0.12 | 0.05 (0.05 to 0.39) | 0.03 |
| IL-10 (pg/mL) | 74.74 ± 113.94 | 31.06 (0 to 431.89) | 8.79 ± 17.46 | 0 (0 to 41.06) | 0.02 |
| IL-12 (pg/mL) | 119.04 ± 312.33 | 0 (0 to 1134.84) | 0 ± 0 | 0 (0 to 0) | 0.02 |
| IL-17A (pg/mL) | 7.1 ± 9.21 | 3.37 (0 to 34.69) | 0.82 ± 1.65 | 0 (0 to 4.29) | 0.01 |
| IL-2 (pg/mL) | 1.9 ± 6.86 | 0 (0 to 24.72) | 0 ± 0 | 0 (0 to 0) | 0.45 |
| IL-4 (pg/mL) | 37.69 ± 61.97 | 14.12 (0 to 228.54) | 5.08 ± 6.38 | 0 (0 to 14.12) | 0.10 |
| IL-5 (pg/mL) | 17.5 ± 40.14 | 0 (0 to 147.07) | 0 ± 0 | 0 (0 to 0) | 0.05 |
| IL-6 (pg/mL) | 3.72 ± 13.42 | 0 (0 to 48.36) | 0 ± 0 | 0 (0 to 0) | 0.45 |
| IL-9 (pg/mL) | 35.15 ± 79.49 | 0 (0 to 290.69) | 0 ± 0 | 0 (0 to 0) | 0.04 |
| IL-1β (pg/mL) | 7.87 ± 11.93 | 1.79 (0 to 34.62) | 1.86 ± 2.62 | 0.18 (0 to 0.98) | 0.32 |
| Folate (ng/mL) | 5.29 ± 2.01 | 6 (1.7 to 8.7) | 12.23 ± 9.07 | 8.5 (2.7 to 25) | 0.24 |
| Vitamin B12 (pg/mL) | 244.85 ± 113.11 | 235 (83 to 463) | 216.89 ± 137.44 | 202 (96 to 566) | 0.25 |
| Vitamin D (ng/mL) | 21.51 ± 9.96 | 23 (6.6 to 39.3) | 21.4 ± 9.81 | 19.3 (13.5 to 46.4) | 0.74 |
Figure 2. Serological biomarkers that were different between the red fruit tea (RFT) and purple corn extract (RED) groups in CD patients at T3 (N: 22).

Table 5. Description of the whole sample of UC patients at the follow-up observation (T3) in UC patients, according to the type of treatment. (N: 25).

|                      | RFT                      | UC                      | RED                      | p-Value |
|----------------------|--------------------------|-------------------------|--------------------------|---------|
| Proportions (%)      | 14 (56.00)               | 11 (44.00)              | 48 (19 to 67)            | 0.62    |
| Age (years)          | 42.57 ± 12.99            | 41 (25 to 69)           | 45.18 ± 16.25            | 0.62    |
| Gender               |                          |                         |                          |         |
| Male                 | 6 (42.90)                | 4 (36.40)               | 4 (0 to 47.34)           | 0.30    |
| Female               | 8 (57.10)                | 7 (63.60)               | 7 (0 to 82.34)           |         |
| IFN-α (pg/mL)        | 5.74 ± 5.2               | 8.85 (0 to 11.05)       | 7.53 ± 5.09              | 0.61    |
| IFN-γ (pg/mL)        | 28.39 ± 73.81            | 1.6 (0 to 281.01)       | 28.57 ± 53.26            | 0.97    |
| TNFα (pg/mL)         | 1 (7.10)                 |                         | 0 (0 to 153.83)          |         |
| CRP (mg/dL)          | 0.77 ± 0.77              | 0.3 (0.05 to 1.9)       | 0.9 ± 1.75               | 0.28    |
| IL-10 (pg/mL)        | 37.54 ± 45.27            | 32.06 (0 to 180.06)     | 32.84 ± 29.96            | 0.85    |
| IL-12 (pg/mL)        | 30.62 ± 114.58           | 0 (0 to 428.72)         | 12.49 ± 30.54            | 0.24    |
| IL-17A (pg/mL)       | 1.9 ± 1.94               | 1.8 (0 to 5.2)          | 2.76 ± 3.1               | 0.65    |
| IL-2 (pg/mL)         | 0 ± 0                    | 0 (0 to 0)              | 0 ± 0                    |         |
| IL-4 (pg/mL)         | 13.87 ± 17.44            | 6.97 (0 to 53.05)       | 9.29 ± 17.59             | 0.32    |
| IL-5 (pg/mL)         | 5.17 ± 19.33             | 0 (0 to 72.33)          | 1.49 ± 4.96              | 0.95    |
| IL-6 (pg/mL)         | 0 ± 0                    | 0 (0 to 0)              | 0 ± 0                    |         |
| IL-9 (pg/mL)         | 11.97 ± 37.24            | 0 (0 to 138.54)         | 9.05 ± 20.34             | 0.83    |
| IL-11β (pg/mL)       | 58.51 ± 203.68           | 2.37 (0 to 765.91)      | 10.01 ± 9.95             | 0.35    |
| Folate (ng/mL)       | 8.73 ± 8.69              | 4.2 (2.8 to 28)         | 7.41 ± 2.58              | 0.41    |
| Vitamin B12 (pg/mL)  | 274.93 ± 131.54          | 239.5 (114 to 533)      | 234.27 ± 69.76           | 0.72    |
| Vitamin D (ng/mL)    | 18.73 ± 7.27             | 20.7 (4.6 to 28.1)      | 19.58 ± 5               | 0.97    |
Despite the reduced number of patients in the groups, results indicated that in CD patients several inflammatory cytokines were significantly reduced, including GM-CSF ($p = 0.04$), IFN-γ ($p = 0.02$), TNFα ($p = 0.04$), IL-5 ($p = 0.04$), IL-10 ($p = 0.02$), IL-12p70 ($p = 0.02$), and IL-17A ($p = 0.01$). Together with these results, the inflammatory biomarker CRP was also significantly reduced by the RED supplement ($p = 0.03$) while iron circulating concentrations were unchanged and ceruloplasmin decreased, but not significantly ($p = 0.06$). Finally, the observed folate increase was non-significant, likely due to the elevated SD in this small sub-group of patients. In UC patients, the only significant variation was a reduction in the BMI, while no inflammatory biomarker or circulating cytokine resulted significantly affected by RED.

4. Discussion

The introduction of biological drugs has been a pivotal moment for IBD treatment, and in particular, the anti-TNFα infusion has become a standard strategy in clinical practice. Disease remission, mucosa healing, and clinical improvement are standard goals for patients receiving IFX infusion. Nonetheless, numerous patients fail to respond to IFX or become secondary non-responders over time.

Currently, the vast majority of research effort is devoted to the development of new drugs, while marginal attention has been paid to adjuvant strategies, particularly nutritional-derived intervention. The gastrointestinal (GI) tract is a complex microenvironment; the molecular crosstalk among the human host, luminal resident microbes, and nutritional intakes plays a pivotal role in physiology, in both physiological and pathological conditions. Epidemiological data indicate the role of diet in IBD onset and relapse, but dietary adjuvant intervention to induce or maintain IBD remission has been little considered in many clinical studies [43–45].

The GI tract surface area is by far the largest border of the body [46] underlined by immune cells, particularly macrophages and dendritic cells (DCs), to patrol the epithelial cell barrier [47]. DCs under the columnar villus epithelium extend processes across this epithelium and interact with the intestinal lumen content, bacteria, food-derived products, and metabolites [48]. During the last decade, we have investigated several aspects of the crosstalk between immune cells and nutritional-derived bioactive compounds and microelements [18–20,49]. With the aim of identifying nutritional-derived bioactive components able to act as adjuvants in IBD treatments, our research groups explored the effects of a large set of antioxidant compounds belonging to the large polyphenols family using both in vitro and in vivo models of gut inflammation [21–28,50,51].

Commercial red fruit tea or purple corn supplement, obtained from B1 Pl1 purple corn cobs, were randomly assigned to IBD patients, both UC and CD, starting on the day of the first IFX infusion. Even in light of the limited number of patients recruited, these data are coherent with previous studies demonstrating an inflammatory suppression effect induced, in vitro and in vivo, by RED administration [31–33].

Our IBD patients cohort was heterogeneous, including UC and CD patients. The present preliminary study aimed to evaluate whether the adjuvant intervention could provide benefits to the vast majority of IBD patients and identify the best responders to this specific antioxidant-enriched strategy. Our results indicated that a daily intake of about 125 mg of purple corn anthocyanins could be effective in suppressing intestinal inflammation and consequently reducing the intestinal leaky barrier characterizing IBD patients [52].

The supplement administration had a different impact in CD or UC patients. Indeed, the analysis of serological biomarkers at the follow-up observation indicates that the impact of the RED extract was mostly relevant in the CD group, where several inflammatory cytokines and CRP were found to be significantly reduced. Our results may indicate that the biological activity of purple corn anthocyanins is exerted mainly in the small intestine. Immune cells exposed to anthocyanins lose the ability to produce and release inflammatory mediators. Immune cells protrusions across the epithelial barrier are more frequent in the ileum as compared to the colon [53,54]. Furthermore, inflammatory conditions increase
the rate of DCs protrusions from the small intestinal villi [46]. Thus, it is possible that, in CD more than in UC patients, intestinal resident DCs could be exposed to purple corn anthocyanins. Another possibility is that the intestinal microbiota may metabolize purple corn anthocyanins, progressively reducing the concentration of bioactive compounds, or else water absorption may reduce their bioavailability, particularly in the distal colon. Therefore, UC patients may require a higher dosage of adjuvant administration or different formulation of the adjuvant.

Overall, the results of the present preliminary study encourage a new larger study based on the administration of purple corn cobs extracts to CD patients starting IFX therapy. Together with the chronic inflammatory syndromes, IBD patients run the risk of developing micronutrient deficiencies. It is important to underline that our results indicate that patients following balanced diets and antioxidant administration show improved iron and folate levels, together with a reduction of numerous inflammatory biomarkers.

5. Conclusions

The present study demonstrated that the purple corn extract (RED) was able to improve patients’ responses to IFX administration, as demonstrated by the reduction of the CRP and ceruloplasmin in the purple corn supplemented group. Our data also make it clear that this supplement was able to reduce inflammatory biomarkers in CD but not in UC patients. Our results may pave the way to a wider multicentric clinical trial focused on supplements administration to CD patients as an adjuvant to anti-TNFα therapy, to improve the disease remission rates and reduce the risk of disease relapse during the maintenance therapy.

Currently, there is some confusion about what dietary intervention may improve the induction and preservation of remission in IBD and their use is challenging. Our single-center study provides the rationale for the design of a specific adjuvant intervention for CDs patients starting the IFX therapy. Further studies will clarify whether different strategies or increased antioxidant concentration may also improve the efficiency of the same supplement in UC patients.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/antiox11010138/s1, Table S1: Bromatological composition of the diet; Table S2: Description of the physical and hematological data across follow-up times (N:47); Statistically significant differences (p-value ≤ 0.05) are underlined in bold; Table S3: Description of physical and hematological data at T3 according to the type of treatment. (N: 47); Statistically significant differences (p-value ≤ 0.05) are underlined in bold; Table S4: Description of physical and hematological data at the follow-up observation (T3) in CD patients, according to the type of treatment. (N: 22). Statistically significant differences (p-value ≤ 0.05) are underlined in bold; Table S5: Description of the whole sample at the follow-up observation (T3) in UC patients, according to the type of treatment. (N: 25). Statistically significant differences (p-value ≤ 0.05) are underlined in bold; Figure S1: Serological biomarkers were significantly different between the T0 and T3 in all the enrolled subjects (N: 47); Figure S2: Serological biomarkers that were significantly different between the red fruit tea (RFT) and purple corn extract (RED) groups at T3 (N: 47); Figure S3: Serological biomarkers that were significantly different between the red fruit tea (RFT) and purple corn extract (RED) groups in UC patients at T3 (N: 25).

Author Contributions: Data curation, M.L., G.V., R.D., F.C., R.S., P.L.P. and A.M.G.; conceptualization, M.C. (Marcello Chieppa), A.S. (Angelo Santino), K.P. and C.T.; formal analysis, M.L., G.V., E.C., D.V., A.S. (Aurelia Scarano) and E.M.S.; investigation, A.S. (Annamaria Sila), M.M. and M.C. (Margherita Curlo); resources, A.L., R.A., P.C., M.C. (Marcello Chieppa), A.S. (Angelo Santino) and A.M.G.; writing, M.L., G.V., A.S. (Annamaria Sila), M.C. (Marcello Chieppa), A.S. (Angelo Santino) and A.M.G.; R.S., K.P. and C.T.; supervision, M.C. (Marcello Chieppa) and A.S. (Angelo Santino). All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by grants from the Italian Ministry of Health (GR-2011-02347991), Ricerca Corrente 2020 IRCCS “S. de Bellis”, from Apulia Region grant SiCURA “Soluzioni Innovative per la gestione del paziente e il follow up terapeutico della Colite UlceroSsA” (KC3U5Y1), PO FESR 2014–2020 “Piattaforme tecnologiche di ricerca collaborativa per la lotta alle patologie
oncologiche”, CNR-DiSBA project NutrAge (project nr. 7022) and from FP7 ATHENA to C.T. (Grant Agreement 245121).

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (Number 333, 31 July 2019) of the National Institute of Gastroenterology “S. de Bellis”, Institute of Research, Castellana Grotte (BA), Italy.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Acknowledgments:** We are grateful to Rita Pace, Margherita Nasuto, and Paola Benedetto for help and support during IFX infusion and samples collection, Pragnell, B.A. for language revision of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Rubin, D.; Shaker, A.; Levin, M. Chronic intestinal inflammation: Inflammatory bowel disease and colitis-associated colon cancer. *Front. Immunol*. 2012, 3, 107. [CrossRef] [PubMed]

2. Lamb, C.A.; Kennedy, N.A.; Raine, T.; Hendy, P.A.; Smith, P.J.; Limdi, J.K.; Hayee, B.H.; Lomer, M.C.E.; Parkes, G.C.; Selinger, C.; et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019, 68, s1. [CrossRef]

3. Lloyd-Price, J.; Arze, C.; Ananthakrishnan, A.N.; Schirmer, M.; Avila-Pacheco, J.; Poon, T.W.; Andrews, E.; Ajami, N.J.; Bonham, K.S.; Brislawn, C.J.; et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature* 2019, 569, 655–662. [CrossRef]

4. van Dullemen, H.M.; van Deventer, S.J.; Hommes, D.W.; Bijl, H.A.; Jansen, J.; Tytgat, G.N.; Woody, J. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). *Gastroenterology* 1995, 109, 129–135. [CrossRef]

5. Mouser, J.F.; Hyams, J.S. Infliximab: A novel chimeric monoclonal antibody for the treatment of Crohn’s disease. *Clin. Ther.* 1999, 21, 932–942, discussion 931. [CrossRef]

6. Siddiqui, M.A.; Scott, L.J. Infliximab: A review of its use in Crohn’s disease and rheumatoid arthritis. *Drugs* 2005, 65, 2179–2208. [CrossRef]

7. Herrlinger, K.R.; Stange, E.F. Twenty-five years of biologicals in IBD: What’s all the hype about? *J. Intern. Med.* 2021, 290, 806–825. [CrossRef]

8. Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. *Lancet* 2017, 390, 2769–2778. [CrossRef]

9. Rizzello, F.; Spisni, E.; Giovanardi, E.; Imbesi, V.; Salice, M.; Alvisi, P.; Valerii, M.C.; Gionchetti, P. Implications of the Westernized Diet in the Onset and Progression of IBD. *Nutrients* 2019, 11, 1033. [CrossRef] [PubMed]

10. Owczarek, D.; Rodacki, T.; Donati, M.B.; Giordano, L.; Mock, H.P.; Peterek, S.; Matros, A.; Petroni, K.; et al. Chronic dietary intake of plant-derived anthocyanins protects the rat heart against ischemia-reperfusion injury. *J. Nutr.* 2020, 150, 747–752. [CrossRef]

11. Mentella, M.C.; Scaldaferri, F.; Pizzoferrato, M.; Gasbarrini, A.; Miggiano, G.A. Dietary fiber and Gut Microbiota: A Review. *Nutrients* 2020, 12, 944. [CrossRef]

12. Joseph, J.A.; Shukitt-Hale, B.; Denisova, N.A.; Bielinski, D.; Martin, A.; McEwen, J.J.; Bickford, P.C. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. *J. Neurosci.* 1999, 19, 8114–8121. [CrossRef]

13. Toufektsian, M.C.; de Lorgeril, M.; Nagy, N.; Salen, P.; Donati, M.B.; Giordano, L.; Mock, H.P.; Peterek, S.; Matros, A.; Petroni, K.; et al. Chronic dietary intake of plant-derived anthocyanins protects the rat heart against ischemia-reperfusion injury. *J. Nutr.* 2020, 150, 747–752. [CrossRef]

14. He, J.; Giusti, M.M. Anthocyanins: Natural colorants with health-promoting properties. *Annu. Rev. Food Sci. Technol.* 2010, 1, 163–187. [CrossRef]

15. Tsuda, T. Dietary anthocyanin-rich plants: Biochemical basis and recent progress in health benefits studies. *Mol. Nutr. Food Res.* 2012, 56, 159–170. [CrossRef] [PubMed]

16. Cassidy, A.; Mukamal, K.J.; Liu, L.; Franz, M.; Eliassen, A.H.; Rimm, E.B. High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. *Circulation* 2013, 127, 188–196. [CrossRef] [PubMed]

17. Jennings, A.; Welch, A.A.; Spector, T.; Macgregor, A.; Cassidy, A. Intakes of anthocyanins and flavones are associated with biomarkers of insulin resistance and inflammation in women. *J. Nutr.* 2014, 144, 202–208. [CrossRef] [PubMed]
Antioxidants 2022, 11, 138

18. De Santis, S.; Liso, M.; Verna, G.; Curci, F.; Milani, G.; Faienza, M.F.; Franchini, C.; Moschetta, A.; Chieppa, M.; Clodoveo, M.L.; et al. Extra Virgin Olive Oil Extracts Modulate the Inflammatory Ability of Murine Dendritic Cells Based on Their Polyphenols Pattern: Correlation between Chemical Composition and Biological Function. Antioxidants 2021, 10, 1016. [CrossRef]

19. Delvecchio, F.R.; Vadrucci, E.; Cavalcanti, E.; De Santis, S.; Kunde, D.; Vacca, M.; Myers, J.; Allen, F.; Bianco, G.; Huang, A.Y.; et al. Polyphenol administration impairs T-cell proliferation by imprinting a distinct dendritic cell maturation profile. Eur. J. Immunol. 2015, 45, 2638–2649. [CrossRef] [PubMed]

20. Cavalcanti, E.; Vadrucci, E.; Delvecchio, F.R.; Addabbo, F.; Bettini, S.; Liou, R.; Monsurro, V.; Huang, A.Y.C.; Pizarro, T.T.; Santino, A.; et al. Administration of reconstituted polyphenol oil bodies efficiently suppresses dendritic cell inflammatory pathways and acute intestinal inflammation. PLoS ONE 2014, 9, e88898.

21. Verna, G.; Liso, M.; Cavalcanti, E.; Bianco, G.; Di Sarno, V.; Santino, A.; Campiglia, P.; Chieppa, M. Quercetin Administration Suppresses the Cytokine Storm in Myeloid and Plasmacytoid Dendritic Cells. Int. J. Mol. Sci. 2021, 22, 8349. [CrossRef] [PubMed]

22. Petroni, K.; Teti, G.; Verna, G.; Liso, M.; Cavalcanti, E.; Sila, A.; Raveenthiran, S.; Mastronardi, M.; Santino, A.; Serino, G.; et al. Quercetin Exposure Suppresses the Inflammatory Pathway in Intestinal Organoids from Winnie Mice. Int. J. Mol. Sci. 2019, 20, 5771. [CrossRef]

23. De Santis, S.; Galleggiante, V.; Scandiffio, L.; Liso, M.; Sommella, E.; Sobolewski, A.; Spilotro, V.; Pinto, A.; Campiglia, P.; Serino, G.; et al. Secretory Leukocyte Protease Inhibitor (Sipi) Expression Is Required for Educating Murine Dendritic Cells Inflammatory Response Following Quercetin Exposure. Nutrients 2017, 9, 706. [CrossRef]

24. De Santis, S.; Kunde, D.; Serino, G.; Galleggiante, V.; Caruso, M.L.; Mastronardi, M.; Cavalcanti, E.; Ranson, N.; Pinto, A.; Campiglia, P.; et al. Secretory leukocyte protease inhibitor is required for efficient quercetin-mediated suppression of TNFβ secretion. Oncotarget 2016, 7, 75800–75809. [CrossRef] [PubMed]

25. Galleggiante, V.; De Santis, S.; Cavalcanti, E.; Scarnano, A.; De Benedictis, M.; Serino, G.; Caruso, M.L.; Mastronardi, M.; Pinto, A.; Campiglia, P.; et al. Dendritic Cells Modulate Iron Homeostasis and Inflammatory Abilities Following Quercetin Exposure. Curr. Pharm. Des. 2017, 23, 2139–2146. [CrossRef]

26. De Santis, S.; Scarnano, A.; Liso, M.; Calabrese, F.M.; Verna, G.; Cavalcanti, E.; Sila, A.; Lippolis, A.; De Angelis, M.; Santino, A.; et al. Polyphenol Enriched Diet Administration During Pregnancy and Lactation Prevents Dysbiosis in Ucerative Colitis Predisposed Littermates. Front. Cell. Infect. Microbiol. 2021, 11, 456. [CrossRef] [PubMed]

27. Liso, M.; De Santis, S.; Scarnano, A.; Verna, G.; Dicarlo, L.; Galleggiante, V.; Campiglia, P.; Mastronardi, M.; Lippolis, A.; Vacca, M.; et al. A Bronze-Tomato Enriched Diet Affects the Intestinal Microbiome under Homeostatic and Inflammatory Conditions. Nutrients 2018, 10, 1862. [CrossRef]

28. Scarnano, A.; Butelli, E.; De Santis, S.; Cavalcanti, E.; Hill, L.; De Angelis, M.; Giovannazzo, G.; Chieppa, M.; Martin, C.; Santino, A. Combined Dietary Anthocyanins, Flavonols, and Stilbenoids Alleviate Inflammatory Bowel Disease Symptoms in Mice. Front. Nutr. 2018, 4, 75. [CrossRef] [PubMed]

29. Achitei, D.; Ciobia, A.; Balan, G.; Gologan, E.; Stanciu, C.; Stefanescu, G. Different profiles of peripheral antioxidant enzymes and lipid peroxidation in active and non-active inflammatory bowel disease patients. Dig. Dis. Sci. 2013, 58, 1244–1249. [CrossRef]

30. Pawar, P.; Gilda, S.; Sharma, S.; Jagtap, S.; Paradkar, A.; Mahadik, K.; Ranjekar, P.; Harsulkar, A. Rectal gel application of Withania somnifera root extract expounds anti-inflammatory and muco-restorative activity in TNBS-induced inflammatory bowel disease. BMC Complement. Altern. Med. 2011, 11, 34. [CrossRef]

31. Petroni, K.; Trinei, M.; Forneri, M.; Calvenzani, V.; Marinelli, A.; Micheli, L.A.; Pili, R.; Matros, A.; Mock, H.P.; Tonelli, C.; et al. Dietary cyanidin 3-glucoside from purple corn ameliorates doxorubicin-induced cardiotoxicity in mice. Nutr. Metab. Cardiovasc. Dis. 2017, 27, 462–469. [CrossRef]

32. Tomay, F.; Marinelli, A.; Leoni, V.; Caccia, C.; Matros, A.; Mock, H.-P.; Tonelli, C.; Petroni, K. Purple corn extract induces long-lasting reprogramming and M2 phenotypic switch of adipose tissue macrophages in obese mice. J. Transl. Med. 2019, 17, 237. [CrossRef]

33. Magni, G.; Marinelli, A.; Riccio, D.; Lecca, D.; Tonelli, C.; Abbraccchio, M.P.; Petroni, K.; Cerutti, S. Purple Corn Extract as Anti-oxidant Treatment for Trigeminal Pain: Role of Microglia. Front. Cell. Neurosci. 2018, 12, 378. [CrossRef]

34. Vermeire, S.; Van Assche, G.; Rutgeerts, P. Classification of inflammatory bowel disease: The old and the new. Curr. Opin. Gastroenterol. 2012, 28, 321–326. [CrossRef] [PubMed]

35. Lewis, J.D.; Chuai, S.; Nessel, L.; Lichtenstein, G.R.; Abero, F.N.; Ellenberg, J.H. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm. Bowel Dis. 2008, 14, 1660–1666. [CrossRef]

36. Sundararajan, V.; Henderson, T.; Perry, C.; Muggivan, A.; Quan, H.; Ghali, W.A. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J. Clin. Epidemiol. 2004, 57, 1288–1294. [CrossRef] [PubMed]

37. Ruemmele, F.M. Role of Diet in Inflammatory Bowel Disease. Ann. Nutr. Metab. 2016, 68 (Suppl. S1), 33–41. [CrossRef]

38. Kakodkar, S.; Mutlu, E.A. Diet as a Therapeutic Option for Adult Inflammatory Bowel Disease. Gastroenterol. Clin. N. Am. 2017, 46, 745–767. [CrossRef] [PubMed]

39. Guigoz, Y.; Vellas, B.; Garry, P.J. Assessing the Nutritional Status of the Elderly: The Mini Nutritional Assessment as Part of the Geriatric Evaluation. Nutr. Rev. 1996, 54, S59–S65. [CrossRef]

40. da Silva Fink, J.; Daniel de Mello, P.; Daniel de Mello, E. Subjective global assessment of nutritional status—A systematic review of the literature. Clin. Nutr. 2015, 34, 785–792. [CrossRef]
41. Bracone, F.; De Curtis, A.; Di Castelnuovo, A.; Pilu, R.; Boccardi, M.; Cilla, S.; Macchia, G.; Deodato, F.; Costanzo, S.; Iacoviello, L.; et al. Skin toxicity following radiotherapy in patients with breast carcinoma: Is anthocyanin supplementation beneficial? *Clin. Nutr.*, 2021, 40, 2068–2077. [CrossRef]

42. Noth, R.; Stüber, E.; Hässler, R.; Nikolaus, S.; Kühbacher, T.; Hampe, J.; Bewig, B.; Schreiber, S.; Arlt, A. Anti-TNF-α antibodies improve intestinal barrier function in Crohn’s disease. *J. Crohns Colitis* 2012, 6, 464–469. [CrossRef] [PubMed]

43. Preda, C.M.; Manuc, T.; Chifulescu, A.; Istratescu, D.; Louis, E.; Baicus, C.; Sandra, I.; Diculescu, M.M.; Reenaers, C.; van Kemseke, C.; et al. Diet as an environmental trigger in inflammatory bowel disease: A retrospective comparative study in two European cohorts. *Rev. Esp. Enferm. Dig.* 2020, 112, 440–447. [CrossRef] [PubMed]

44. Grosse, C.S.J.; Christophersen, C.T.; Devine, A.; Dave, V.; Lawrance, I.C. The role of a plant-based diet in the pathogenesis, etiology and management of the inflammatory bowel diseases. *Expert Rev. Gastroenterol. Hepatol.* 2020, 14, 137–145. [CrossRef]

45. Schreiner, P.; Martinho-Grueber, M.; Studerus, D.; Vavricka, S.R.; Tilg, H.; Biedermann, L. Nutrition in Inflammatory Bowel Disease. *Digestion* 2020, 101 (Suppl. S1), 120–135. [CrossRef] [PubMed]

46. Rescigno, M.; Chieppa, M. Gut-level decisions in peace and war. *Nat. Med.* 2005, 11, 254–255. [CrossRef]

47. Eri, R.; Chieppa, M. Messages from the Inside. The Dynamic Environment that Favors Intestinal Homeostasis. *Front. Immunol.* 2013, 4, 323. [CrossRef]

48. Rescigno, M.; Lopatin, U.; Chieppa, M. Interactions among dendritic cells, macrophages, and epithelial cells in the gut: Implications for immune tolerance. *Curr. Opin. Immunol.* 2008, 20, 669–675. [CrossRef]

49. Verna, G.; Liso, M.; De Santis, S.; Dicarlo, M.; Cavalcanti, E.; Crovace, A.; Sila, A.; Campiglia, P.; Santino, A.; Lippolis, A.; et al. Iron overload mimicking conditions skews bone marrow dendritic cells differentiation into mhiilowcd11c+cd11b+f4/80+ cells. *Int. J. Mol. Sci.* 2020, 21, 1353. [CrossRef]

50. Verna, G.; Sila, A.; Liso, M.; Mastronardi, M.; Chieppa, M.; Cena, H.; Campiglia, P. Iron-Enriched Nutritional Supplements for the 2030 Pharmacy Shelves. *Nutrients* 2021, 13, 378. [CrossRef]

51. Scarano, A.; Chieppa, M.; Santino, A. Plant Polyphenols-Biofortified Foods as a Novel Tool for the Prevention of Human Gut Diseases. *Antioxidants* 2020, 9, 1225. [CrossRef] [PubMed]

52. Li, S.; Wu, B.; Fu, W.; Reddivari, L. The Anti-inflammatory Effects of Dietary Anthocyanins against Ulcerative Colitis. *Int. J. Mol. Sci.* 2019, 20, 2588. [CrossRef] [PubMed]

53. Rimoldi, M.; Chieppa, M.; Salucci, V.; Avogadri, F.; Sonzogni, A.; Sampietro, G.M.; Nespoli, A.; Viale, G.; Allavena, P.; Rescigno, M. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. *Nat. Immunol.* 2005, 6, 507–514. [CrossRef] [PubMed]

54. Chieppa, M.; Rescigno, M.; Huang, A.Y.C.; Germain, R.N. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. *J. Exp. Med.* 2006, 203, 2841–2852. [CrossRef]